Northlane Capital Partners has made an investment in SAI MedPartners, a healthcare consulting firm.
SAI MedPartners (SAI) provides intelligence and strategy support services across the product development lifecycle to companies in the pharmaceutical, biotechnology, and medical devices sectors. SAI, led by founder and CEO Erik Nordhoy, is headquartered in Reading, Pennsylvania, and has more than 300 employees located across the United States, Europe, and Asia.
“SAI is our team’s 30th platform investment and fits squarely in our pharmaceutical services focus within our healthcare vertical,” said Justin DuFour, a partner at NCP. “We have significant experience investing in similar business models within SAI’s end markets and look forward to assisting SAI in its next phase of growth.”
“We are thrilled to partner with NCP, which has an impressive track record of investing in businesses that support the pharmaceutical and medical device industries,” said Mr. Nordhoy, “SAI’s rapid organic growth over the past decade has been driven by a singular focus on being the best thought partner and provider of high-quality strategic intelligence and related advisory services to our clients. NCP’s investment will allow us to further strengthen our client engagement model by providing us with the resources to significantly augment our suite of services and continue to expand globally.”
Northlane invests in companies that have EBITDA of $5 million to $30 million and are active in the healthcare and business services sectors. The Bethesda, Maryland-based firm was formed through the January 2017 spinout of American Capital Equity III LP from American Capital as a result of the acquisition of the company by Ares Capital.
“We are delighted to have the opportunity to partner with Erik and the rest of the SAI management team,” said Eugene Krichevsky, a partner at NCP. “SAI has established itself as a global leader in the life sciences competitive intelligence market. NCP is in complete alignment with SAI’s strategic roadmap of adding resources and expanding the capabilities of the business to increase its value proposition to key customers and stakeholders.”
Northlane is actively looking for add-on acquisitions for the SAI that provide complementary or competitive services, or companies that provide adjacent services that assist companies with drug development and commercialization process.
In April 2021, Northlane held an above-target close of Northlane Capital Partners II LP (NCP II) with total capital commitments of $408 million.
Northlane Capital Partners is headquartered in Bethesda, Maryland.
© 2022 Private Equity Professional | July 6, 2022
